1-17 of 17
Kavita Sail
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont
Journal: Blood
Blood (2024) 144 (Supplement 1): 2349.
https://doi.org/10.1182/blood-2024-203994
Published: 2024
Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont
Journal: Blood
Blood (2023) 142 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2023-180047
Published: 2023
Journal Articles

Real-World Response Rates across Lines of Therapy Among Patients with Relapsed/Refractory Follicular Lymphoma

Tycel Philips, Laurie H. Sehn, Anthony Wang, Junhua Yu, Elizabeth H. Marchlewicz, Rajesh Kamalakar, Kavita Sail, Donald Arnette, Shibing Yang, Alex Mutebi, Fernando Rivas Navarro, Gilles Salles
Journal: Blood
Blood (2023) 142 (Supplement 1): 1683.
https://doi.org/10.1182/blood-2023-180088
Published: 2023
Journal Articles

Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis

Kalatu R. Davies, Rajesh Kamalakar, Junhua Yu, Yinan Huang, Anthony Wang, Kavita Sail, Thomas Doerr, Simon Sharmokh, Alex Mutebi, Gilles Salles
Journal: Blood
Blood (2022) 140 (Supplement 1): 5058–5059.
https://doi.org/10.1182/blood-2022-157758
Published: 2022
Journal Articles

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Matthew S. Davids, Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai, Brenda Chyla, Kavita Sail, John Pesko, Madhavi Pai, Viktor Komlosi, Michael Hallek, Jennifer R. Brown, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 2634.
https://doi.org/10.1182/blood-2021-153033
Published: 2021
Journal Articles

Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France

Honghao Fang, Harinala Ravonimbola, Nisha C Hazra, Zhou Zhou, MS, Beenish S. Manzoor, PhD MPH, Vincent Levy, MD PhD, Loic Ysebaert, MD PhD, Nathanael Kabore, Kavita Sail
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-137034
Published: 2020
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

Anuja Chatterjee, MSc, Gijs Van de Wetering, PhD, Ron Goeree, Anne Marie Desbois, Patricia Manzi, MSc, BPharm, Beenish S Manzoor, PhD, Carolyn Owen, MDFRCPC, Kavita Sail, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-134596
Published: 2020
Journal Articles

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Dandan Zheng, Kavita Sail, PhD, Lindsey E Roeker, MD, Beenish S Manzoor, PhD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Toby A. Eyre, Alan Skarbnik, MD, Rajat Bannerji, MDPhD, Barbara Eichhorst, MD, Danielle M. Brander, MD, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Rajesh Kamalakar, MS, Nnadozie Emechebe, MPH, Irina Pivneva, Rebecca Burne, Annie Guerin, MSc, Matthew S. Davids, MD, Anthony Mato, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–22.
https://doi.org/10.1182/blood-2020-134676
Published: 2020
Journal Articles

Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen

Meghan C. Thompson, MD, John N. Allan, MD, Kavita Sail, PhD, Beenish S. Manzoor, PhD MPH, Jeffrey J. Pu, MD PhD, Paul M. Barr, MD, Catherine C. Coombs, MD, Stephen J. Schuster, MD, Alan Skarbnik, MD, Joanna M Rhodes, MD, Jacqueline C. Barrientos, MD, Lindsey E Roeker, MD, Lori A. Leslie, MD, Manali Kamdar, MD, Michael Y. Choi, MD, Martin Simkovic, MD PhD, Frederick Lansigan, MD, Brittany Jane Hale, MD, Andrew D Zelenetz, MD PhD, Alison J. Moskowitz, MD, Kurt S. Bantilan, MPH, Celina J. Komari, BS, Andre H. Goy, MD, Tatyana A. Feldman, MD, Richard R. Furman, MD, Anthony R. Mato, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-138725
Published: 2020
Journal Articles

Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies

Anthony R. Mato, MDMSCE, Kavita Sail, PhD, Maryam Sarraf Yazdy, MD, Brian T. Hill, MD, Mazyar Shadman, MD MPH, Beenish S Manzoor, PhD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Thomas Marshall, PharmD, MS, Jacqueline Nielsen, PhD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Anna Schuh, PhD, Toby A. Eyre, MD, William G. Wierda, MD PhD, Alan Skarbnik, MD, Lindsey E. Roeker, MD, Rajat Bannerji, MD PhD, James M. Pauff, MD PhD, Stephen J. Schuster, MD, George A Follows, MD PhD, Bruce D. Cheson, MD, Barbara F. Eichhorst, MD, Danielle M. Brander, MD, Irina Pivneva, PhD, Nicole Lamanna, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1756.
https://doi.org/10.1182/blood-2019-124600
Published: 2019
Journal Articles

Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study

Mazyar Shadman, MD MPH, Kavita Sail, PhD, Beenish S Manzoor, PhD, Maryam Sarraf Yazdy, MD, Brian T. Hill, MD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Nnadozie Emechebe, MPH, Rajesh Kamalakar, MS, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Thomas Marshall, PharmD, MS, Jacqueline Nielsen, PhD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Anna Schuh, PhD, Toby A. Eyre, MD, Nicole Lamanna, MD, William G. Wierda, MD PhD, Alan Skarbnik, MD, Lindsey E. Roeker, MD, Rajat Bannerji, MD PhD, James M. Pauff, MD PhD, Stephen J. Schuster, MD, George A Follows, MD PhD, Bruce D. Cheson, MD, Barbara F. Eichhorst, MD, Danielle M. Brander, MD, Irina Pivneva, PhD, Annie Guerin, MSc, Anthony R. Mato, MDMSCE
Journal: Blood
Blood (2019) 134 (Supplement_1): 3048.
https://doi.org/10.1182/blood-2019-131401
Published: 2019
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 4741.
https://doi.org/10.1182/blood-2019-123706
Published: 2019
Journal Articles

Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial

Othman Al-Sawaf, MD, Brittany Gentile, PhD, Jacob Devine, MA, Kavita Sail, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Nadine Kutsch, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4305.
https://doi.org/10.1182/blood-2019-126542
Published: 2019
Journal Articles

Venetoclax Improves Quality of Life for Patients with Elapsed/Refractory Chronic Lymphocytic Leukemia

Tara Cochrane, BMBS, FRACP, FRCPA, Tatiana Chagorova, MD, Tadeusz Robak, MD PhD, Su-Peng Yeh, MD, Evgeny Nikitin, MD, Madlaina Breuleux, PhD DAS, Abdullah Masud, PhD, Kavita Sail, PhD, Viktor Komlosi, MD PhD, Mary Ann Anderson, FRACP, FRCPA, MBBS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4858.
https://doi.org/10.1182/blood-2018-99-117127
Published: 2018
Journal Articles

Treatment Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with B-Cell Receptor Inhibitors (BCRis) in Canada—a Medical Chart Review Study

Tazmin Merali, Patricia Manzi, MSc, BPharm, Diptavo Dutta, Sandra Tremblay, Birgitta Dietz, Jenna Khamis, Shaniah Leduc, Kavita Sail, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5612.
https://doi.org/10.1182/blood.V130.Suppl_1.5612.5612
Published: 2017
Journal Articles

Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review

Miguel A. Pavlovsky, MD, Kavita Sail, PhD, Leonardo Passos Chaves, MD MSc, Rajesh Kamalakar, MS, Xiaojing Ma, MS, Patricia Brandalise, MD MSC, Carlos Chiattone, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5617.
https://doi.org/10.1182/blood.V130.Suppl_1.5617.5617
Published: 2017
Journal Articles

Lifetime Costs of Patients with Chronic Lymphocytic Leukemia

Kavita Sail, PhD, Alison Sexton Ward, PhD, Reethi Iyenger, PhD, Alison Silverstein, PhD, Oliver Diaz Espinosa, Holger Keim, PhD, Brian Meissner, PharmD, PhD, Melissa Frasco, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5621.
https://doi.org/10.1182/blood.V130.Suppl_1.5621.5621
Published: 2017